QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, August 22, 2007, 27(34):9155-9168; doi:10.1523/JNEUROSCI.5492-06.2007

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dawson, H. N. Articles by Vitek, M. P. Search for Related Content PubMed PubMed Citation Articles by Dawson, H. N. Articles by Vitek, M. P.

 Previous Article  |  Next Article 

Neurobiology of Disease
The Tau N279K Exon 10 Splicing Mutation Recapitulates Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 Tauopathy in a Mouse Model

Hana N. Dawson, Viviana Cantillana, Liling Chen, and Michael P. Vitek

Division of Neurology, Duke University, Durham, North Carolina 27710

Correspondence should be addressed to Hana N. Dawson, Division of Neurology, Duke University, P.O. Box 2900, Durham, NC 27710. Email: dawso009{at}mc.duke.edu

Intracellular tau deposits are characteristic of several neurodegenerative disorders called tauopathies. The tau protein regulates the stability and assembly of microtubules by binding to microtubules through three or four microtubule-binding repeats (3R and 4R). The number of microtubule-binding repeats is determined by the inclusion or exclusion of the second microtubule-binding repeat encoded by exon 10 of the TAU gene. TAU gene mutations that alter the inclusion of exon 10, and hence the 4R:3R ratio, are causal in the tauopathy frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). A mutation located in exon 10 has been identified in several FTDP-17 families that present with increased exon 10 inclusion in both mRNA and protein, parkinsonism, movement disorders, and dementia. We have engineered a human tau minigene construct that was designed to allow alternative splicing of the tau exon 10. Here we demonstrate that transgenic mice expressing human tau protein with this mutation develop neurodegeneration as result of aberrant splicing. The mice recapitulate many of the disease hallmarks that are seen in patients with this mutation, including increased tau exon 10 inclusion in both mRNA and protein, motor and behavioral deficits, and tau protein accumulation in neurons and tufted astrocytes. Furthermore, these mice present with degeneration of the nigrostriatal dopaminergic pathway, suggesting a possible mechanism for parkinsonism in FTDP-17. Additionally, activated caspase-3 immunoreactivity in both neurons and astrocytes implicates the involvement of the apoptotic pathway in the pathology of these mice.

Key words: promoter; astrocytes; parkinsonian disorders; motor skills disorders; caspase-3; tauopathy

---

Received July 20, 2006; revised June 28, 2007; accepted June 29, 2007.

Correspondence should be addressed to Hana N. Dawson, Division of Neurology, Duke University, P.O. Box 2900, Durham, NC 27710. Email: dawso009{at}mc.duke.edu

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help